Orchid Pharma Limited (NSE:ORCHPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 29.69B |
| Revenue (ttm) | 8.11B |
| Net Income (ttm) | 190.61M |
| Shares Out | 50.72M |
| EPS (ttm) | 3.77 |
| PE Ratio | 155.25 |
| Forward PE | 23.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,923 |
| Average Volume | 78,219 |
| Open | 588.25 |
| Previous Close | 585.30 |
| Day's Range | 587.55 - 624.80 |
| 52-Week Range | 480.00 - 899.00 |
| Beta | 0.36 |
| RSI | 58.83 |
| Earnings Date | May 22, 2026 |
About Orchid Pharma
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly... [Read more]
Financial Performance
In fiscal year 2025, Orchid Pharma's revenue was 9.22 billion, an increase of 12.52% compared to the previous year's 8.19 billion. Earnings were 996.57 million, an increase of 8.13%.
Financial StatementsNews
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Orchid Pharma Ltd (BOM:524372) Q3 2026 Earnings Call Highlights: Navigating Challenges with ...
Orchid Pharma Ltd (BOM:524372) Q3 2026 Earnings Call Highlights: Navigating Challenges with Strategic Expansions and R&D Investments
Q3 2026 Orchid Pharma Ltd Earnings Call Transcript
Q3 2026 Orchid Pharma Ltd Earnings Call Transcript
Orchid Pharma Transcript: Q3 25/26
Q3 FY26 saw a 5% YoY sales decline and margin compression due to global antibiotic market stress and lower regulated market sales. Cost optimization and R&D investments continue, while new launches and the 7-ACA project are expected to drive future growth.
Orchid Pharma shares slip over 3% as Q3 EBITDA falls 94.2% YoY to Rs 1.5 crore
Orchid Pharma shares slipped more than 3% in early trade on February 12 (IST) after the company reported a sharp...
Orchid Pharma Ltd (BOM:524372) Q2 2026 Earnings Call Highlights: Strategic Acquisitions and ...
Orchid Pharma Ltd (BOM:524372) Q2 2026 Earnings Call Highlights: Strategic Acquisitions and Sales Growth Amid Market Challenges
Q2 2026 Orchid Pharma Ltd Earnings Call Transcript
Q2 2026 Orchid Pharma Ltd Earnings Call Transcript
Orchid Pharma Transcript: Q2 25/26
Q2 FY26 saw a 13% YoY sales decline but sequential improvement, with gross margin compression due to weak pricing and inventory liquidation. Strategic acquisition of emmetazobactam rights positions for future growth, while the antibiotics market remains under pressure.
Orchid Pharma Transcript: Q1 25/26
Q1 FY26 saw a 29% sales decline due to a global antibiotics slowdown, but gross margins were preserved at 42%. The company acquired global rights to Enmetazobactam, expects no debt for the deal, and is focused on disciplined execution and margin protection amid ongoing market contraction.
Top stocks to buy today: Stock recommendations for July 16, 2025 - check list
Stock market recommendations: Anand Rathi Shares suggests buying Tilak Nagar Industries, Orchid Pharma, and ITC. Tilak Nagar Industries shows range breakout with volume support. Orchid Pharma indicate...
Orchid Pharma shares drop nearly 5% as Q4 net profit falls 32.4% YoY to Rs 22.3 crore
Orchid Pharma witnessed a sharp decline in its stock price, falling nearly 5% following the release of its fourth-quarter results for FY25. As of 10:11 AM, the shares were trading 4.98% lower at Rs 70...
Orchid Pharma Transcript: Q4 24/25
Q4 and FY2024 saw double-digit sales and EBITDA growth, but ongoing pricing pressure and project delays are expected to mute FY2026 performance. The AMS division is building scale, Enmetazobactam is outperforming in India, and the Dhanuka merger is set to strengthen the business.
Orchid Pharma shares surge 4.4% after successful USFDA inspection at Alathur API facility
Orchid Pharma Ltd. saw a 4% jump in its stock price following the successful completion of a surprise inspection by the United States Food and Drug Administration (USFDA) at its Active Pharmaceutical ...
Orchid Pharma successfully completes USFDA inspection at Alathur API facility, secures EU GMP certification renewal
Orchid Pharma Limited has announced the successful completion of a surprise USFDA inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection...
Orchid Pharma shares drop over 14% as net profit falls 25.63% YoY to ₹22.45 crore in Q3
Orchid Pharma witnessed a sharp decline of over 14% in its stock price after the company reported weak financial results for Q3. As of 10:27 AM, the shares were trading 14.78% lower at Rs 1,051.65. Fo...
Orchid Pharma Transcript: Q3 24/25
Q3 FY25 saw 15% YoY revenue growth and 26% PAT increase, with strong volume gains offset by price corrections in key products. Strategic investments in AMS and 7-ACA continue, while royalty income from Europe is ramping up. Gross margins remain stable at 40% ±2%.
Orchid Pharma shares jump nearly 4% following strong Q2 FY25 results
Orchid Pharma shares rose by 3.94%, trading at ₹1,509.90 on the NSE as of 11:29 am, driven by impressive Q2 FY25 financial results showcasing robust growth in revenue and profitability. Key Financial ...
Orchid Pharma Transcript: Q2 24/25
Q2 FY25 sales reached INR 222.7 crores, with H1 sales up 22% year-over-year and EBITDA rising to INR 78.6 crores. Orblicef launched in India, Enmetazobactam sales began in the EU, and capacity expansion projects are on track. Management remains optimistic about future growth.
Orchid Pharma Q2 FY25 Results: Revenue jumps 12% to ₹222.7 crore, PAT up 26% YoY
Orchid Pharma announced its Q2 FY25 results, reflecting strong growth in revenue and profitability. The company continues to benefit from efficient cost management and operational improvements, leadin...
Orchid Pharma Transcript: Q1 24/25
Q1 FY25 saw 34% revenue and 71% EBITDA growth, driven by strong capacity utilization and cost control. New product launches, major CapEx projects, and a Cipla partnership position the company for sustained growth, with full-year revenue expected to rise 20–25%.